Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340066 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence
A Phase 1 study, sponsored by Beech Tree Labs.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT01340066: Completed Phase 1 study, sponsored by Beech Tree Labs.
NCT01340066 is a Phase 1 study that has completed, run by Beech Tree Labs. The registered enrollment target is 94 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01340066, a Phase 1 study, has completed, sponsored by Beech Tree Labs.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.
Primary Outcome
Incontinence events were recorded on a daily diary. Leaks were scored and tabulated for a daily score. These values were utilized to come up with total of leakage events during the double-blind treatment period.
Interventions
- DRUG matching placebo
- DRUG UISH001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
What the finished NCT01340066 record still lists
NCT01340066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 2 interventions - of which matching placebo is the first listed.
NCT01340066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01340066 about?
NCT01340066 is a clinical study titled "Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence". The purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.
What is the current status of trial NCT01340066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2011-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01340066?
The interventions under investigation include: matching placebo (DRUG), UISH001 (DRUG).
Who is sponsoring clinical trial NCT01340066?
This trial is sponsored by Beech Tree Labs, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01340066's enrollment target sits among peer trials
94 615th of 2000 higher than 1,377 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia